Erik A C Wiemer

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint The role of microRNAs in cancer: no small matter
    Erik A C Wiemer
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    Eur J Cancer 43:1529-44. 2007
  2. pmc MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α
    Caroline M M Gits
    Department of Medical Oncology, Erasmus University Medical Center Erasmus MC Cancer Institute, Rotterdam, The Netherlands
    BMC Cancer 14:429. 2014
  3. doi request reprint A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients
    Karel Eechoute
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 18:5780-7. 2012
  4. ncbi request reprint MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors
    Caroline M M Gits
    Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    Int J Cancer 135:348-61. 2014
  5. doi request reprint Drug transporters and imatinib treatment: implications for clinical practice
    Karel Eechoute
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 17:406-15. 2011
  6. doi request reprint Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study
    Jessica M van der Bol
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 47:831-8. 2011
  7. doi request reprint Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy
    Anne Joy M de Graan
    Department of Medical Oncology and Trials and Statistics, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 18:4425-32. 2012
  8. doi request reprint Drug transporters of platinum-based anticancer agents and their clinical significance
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Drug Resist Updat 14:22-34. 2011
  9. pmc Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study
    Inge R H M Konings
    Department of Medical Oncology, Erasmus University Medical Center, Room HE 118, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 67:1055-62. 2011
  10. pmc CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity
    Anne Joy M de Graan
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 19:3316-24. 2013

Collaborators

Detail Information

Publications42

  1. ncbi request reprint The role of microRNAs in cancer: no small matter
    Erik A C Wiemer
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    Eur J Cancer 43:1529-44. 2007
    ....
  2. pmc MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α
    Caroline M M Gits
    Department of Medical Oncology, Erasmus University Medical Center Erasmus MC Cancer Institute, Rotterdam, The Netherlands
    BMC Cancer 14:429. 2014
    ..MicroRNAs (miRNAs) play a role in the regulation of the tumor cell response to hypoxia, however, not much is known about the involvement of miRNAs in hypoxic signalling pathways in soft tissue sarcomas (STS)...
  3. doi request reprint A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients
    Karel Eechoute
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 18:5780-7. 2012
    ..As imatinib is mainly metabolized in the liver, our secondary aim was to elucidate the potential effects of the volume of liver metastases on exposure to imatinib...
  4. ncbi request reprint MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors
    Caroline M M Gits
    Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    Int J Cancer 135:348-61. 2014
    ..In addition, our data indicate that miR-145 and miR-451 act as tumor suppressors in adipose tissue and show that re-expression of these miRNAs could be a promising therapeutic strategy for liposarcomas. ..
  5. doi request reprint Drug transporters and imatinib treatment: implications for clinical practice
    Karel Eechoute
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 17:406-15. 2011
    ..In addition, more pharmacogenetic studies will be needed to validate associations...
  6. doi request reprint Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study
    Jessica M van der Bol
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 47:831-8. 2011
    ..In this open-label cross-over study we investigated the effects of omeprazole on the pharmacokinetics and toxicities of irinotecan...
  7. doi request reprint Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy
    Anne Joy M de Graan
    Department of Medical Oncology and Trials and Statistics, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 18:4425-32. 2012
    ..The main objective of this study was to examine the effects of smoking on the pharmacokinetics and toxicities of patients treated with docetaxel or paclitaxel...
  8. doi request reprint Drug transporters of platinum-based anticancer agents and their clinical significance
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Drug Resist Updat 14:22-34. 2011
    ..In addition, transporter-mediated tumour resistance, the impact of potential platinum transporter-mediated drug-drug interactions, and the role of drug transporters in the renal elimination of platinum compounds are discussed...
  9. pmc Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study
    Inge R H M Konings
    Department of Medical Oncology, Erasmus University Medical Center, Room HE 118, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 67:1055-62. 2011
    ..Sampling for measurement of 5-fluorouracil in tumor tissue was performed using microdialysis...
  10. pmc CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity
    Anne Joy M de Graan
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 19:3316-24. 2013
    ..Neurotoxicity is one of the most prominent side effects of paclitaxel. This study explores potential predictive pharmacokinetic and pharmacogenetic determinants for the onset and severity of neurotoxicity...
  11. doi request reprint Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding
    Peter de Bruijn
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    J Pharm Biomed Anal 59:117-22. 2012
    ..The within-run and between-run precisions in this range were within 4.99%, while the accuracy ranged from 95.8 to 100.3%. The method was successfully applied to samples derived from a clinical study...
  12. doi request reprint Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation
    Maja J A de Jonge
    Erasmus University Medical Center Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    Eur J Cancer 46:3016-21. 2010
    ..v.) LiPlaCis. and to assess plasma and urine pharmacokinetics and plasma biomarkers...
  13. pmc Effects of methimazole on the elimination of irinotecan
    Jessica M van der Bol
    Department of Medical Oncology, Erasmus MC University Hospital, Daniel den Hoed Cancer Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 67:231-6. 2011
    ..To study the possible pharmacokinetic and pharmacodynamic interactions between irinotecan and methimazole...
  14. doi request reprint Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry
    Peter de Bruijn
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    J Pharm Biomed Anal 50:977-82. 2009
    ..00 ng/ml. The within-run and between-run precisions were within 7.90%, while the accuracy ranged from 92.2% to 99.7%. The method was successfully applied to samples derived from a clinical study...
  15. doi request reprint The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin
    Marijn T M van Jaarsveld
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 49:345-51. 2013
    ..Since RSK2 is frequently amplified in a growing number of cancers, this may have implications for the sensitivity of these tumours to platinum-based cytotoxics...
  16. ncbi request reprint RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Daniel den Hoed Kliniek Josephine Nefkens Institute, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 9:827-36. 2003
    ..The aim of this study was to investigate whether expression of particular drug resistance genes in primary operable breast cancer correlates with response to first-line chemotherapy in advanced disease...
  17. pmc Application of prolonged microdialysis sampling in carboplatin-treated cancer patients
    Inge R H M Konings
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 64:509-16. 2009
    ..We explored the feasibility of microdialysis in tumor tissue for multiple days in a clinical setting, using carboplatin as model drug...
  18. doi request reprint Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen
    Lisette Binkhorst
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Breast Cancer Res Treat 139:923-9. 2013
    ..Co-medication should be reviewed by both physicians and pharmacists and potent CYP2D6 inhibitors ought to be switched to weaker alternatives. ..
  19. pmc Evaluation of patient enrollment in oncology phase I clinical trials
    Diane A J van der Biessen
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Oncologist 18:323-9. 2013
    ..The main aim of this study was to gain insight into the motivations and other variables influencing patients in their decision to participate in phase I oncology trials...
  20. doi request reprint Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry
    Lisette Binkhorst
    Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Pharm Biomed Anal 56:1016-23. 2011
    ..0% and accuracy ranging from 89.5 to 105.3%. The method has been applied to samples from a clinical study and cross-validated with a validated LC-MS/MS method in serum...
  21. doi request reprint Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
    Walter J Loos
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    J Pharm Biomed Anal 54:387-94. 2011
    ..7 to 110.6%. The applicability of the bioanalytical method was demonstrated and is currently implemented in a clinical trial to study DM as probe-drug for individualized tamoxifen treatment in breast cancer patients...
  22. doi request reprint Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
    Peter de Bruijn
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    J Pharm Biomed Anal 51:934-41. 2010
    ..200 to 50.0ng/ml with the lower limit of quantitation validated at 0.200ng/ml for both sunitinib and SU12662. The within-run and between-run precisions were within 11.7%, while the accuracy ranged from 90.5 to 106.8%...
  23. ncbi request reprint DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity
    Marijn T M van Jaarsveld
    Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    Mol Oncol 8:458-68. 2014
    ..In conclusion, we provide evidence that DNA damage responsive microRNAs are frequently misexpressed in human cancer and can modulate chemotherapy sensitivity. ..
  24. ncbi request reprint Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Biol Ther 4:1270-4. 2005
    ..The latter may imply that these wild-type c-KIT and PDGFR tumor types will probably not benefit from imatinib treatment...
  25. doi request reprint Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Breast Cancer Res Treat 138:47-57. 2013
    ..The discrepancy between E-cadherin loss and EMT was thus reproduced in clinical samples. Together, these results indicate that in human breast cancer loss of E-cadherin is not causal for EMT and even not a necessity...
  26. doi request reprint A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan
    Jessica M van der Bol
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 16:736-42. 2010
    ..A randomized trial was done to assess the utility of an algorithm for individualized irinotecan dose calculation based on a priori CYP3A4 activity measurements by the midazolam clearance test...
  27. ncbi request reprint Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Daniel den Hoed Kliniek Josephine Nefkens Institute, Rotterdam, The Netherlands
    Blood 104:2940-2. 2004
    ..Since BCRP is highly expressed in the gastrointestinal tract, BCRP might not only play a role in cellular resistance of tumor cells but also influence the gastrointestinal absorption of imatinib...
  28. ncbi request reprint Incident cancer risk after the start of aspirin use: results from a Dutch population-based cohort study of low dose aspirin users
    Loes M Hollestein
    Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Int J Cancer 135:157-65. 2014
    ..75, 95% CI 0.59-0.96). However, a clear dose-response relationship was not observed (adjusted HR >6 years aspirin use 0.95, 95% CI 0.60-1.49). Our results do not support the primary prevention of cancer among long term aspirin users. ..
  29. pmc MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation
    Dmitry Zubakov
    Department of Forensic Molecular Biology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Int J Legal Med 124:217-26. 2010
    ..Additional work remains necessary in search for suitable miRNA markers for other forensically relevant body fluids...
  30. ncbi request reprint ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients
    Bronno van der Holt
    Department of Trials and Statistics HOVON Dutch Belgian Hemato Oncology Cooperative Group Data Center, Erasmus MC Daniel den Hoed Cancer Center and Sophia Children s Hospital, Rotterdam, The Netherlands
    Clin Pharmacol Ther 80:427-39. 2006
    ....
  31. ncbi request reprint The relevance of microdialysis for clinical on:cology
    Jos J E M Kitzen
    Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Curr Clin Pharmacol 1:255-63. 2006
    ..Although faced with some methodological challenges, the technique offers many advantages over others, and enables direct tumor assessment for pharmacokinetics and even pharmacodynamics...
  32. ncbi request reprint Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope
    Arend van Zon
    Department of Hematology, Erasmus Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Exp Cell Res 312:245-55. 2006
    ..We hypothesize that a subset of vaults moves directionally via microtubules, possibly towards the nucleus...
  33. doi request reprint MicroRNAs in ovarian cancer biology and therapy resistance
    Marijn T M van Jaarsveld
    Dept of Medical Oncology, Josephine Nefkens Institute, Erasmus MC, 3015 GE Rotterdam, The Netherlands
    Int J Biochem Cell Biol 42:1282-90. 2010
    ..In the final section, we speculate on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools...
  34. ncbi request reprint Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics
    Marieke H Mossink
    Department of Hematology, Erasmus University Rotterdam, 3015 GE Rotterdam, The Netherlands
    Cancer Res 62:7298-304. 2002
    ..Both groups of mice responded similarly to the doxorubicin treatment. Our results suggest that MVP/vaults are not directly involved in the resistance to cytostatic agents...
  35. pmc Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
    John A Foekens
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute, 3000 CA Rotterdam, The Netherlands
    Proc Natl Acad Sci U S A 105:13021-6. 2008
    ..In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein...
  36. ncbi request reprint Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Biol Ther 4:747-52. 2005
    ....
  37. ncbi request reprint Vaults: a ribonucleoprotein particle involved in drug resistance?
    Marieke H Mossink
    Department of Hematology, Erasmus Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Oncogene 22:7458-67. 2003
    ..Here, we review the current knowledge on the vault complex and critically discuss the evidence that links vaults to drug resistance...
  38. ncbi request reprint Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression
    Arend van Zon
    Department of Hematology, Erasmus Medical Center, 3000 DR Rotterdam, The Netherlands
    Cancer Res 64:4887-92. 2004
    ..Our results indicate that vaults are not directly involved in the sequestration of anthracyclines in vesicles nor in their efflux from the nucleus...
  39. ncbi request reprint Major vault protein, in concert with constitutively photomorphogenic 1, negatively regulates c-Jun-mediated activator protein 1 transcription in mammalian cells
    Chunling Yi
    Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520 8104, USA
    Cancer Res 65:5835-40. 2005
    ..Taken together, we propose that MVP, most likely through its interaction with COP1, suppresses c-Jun-mediated AP-1 transcription under unstressed conditions, thereby preventing cells from undergoing stress response...
  40. ncbi request reprint Up-regulation of drug resistance-related vaults during dendritic cell development
    Anouk B Schroeijers
    Departments of Pathology and Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    J Immunol 168:1572-8. 2002
    ..These data point to a role for vaults in both DC survival and functioning as APC...
  41. ncbi request reprint The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling
    Sivanagarani Kolli
    Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520 8066, USA
    J Biol Chem 279:29374-85. 2004
    ..We propose that MVP functions as a novel scaffold protein for both SHP-2 and Erk. The regulation of MVP tyrosyl phosphorylation by SHP-2 may play an important role in cell survival signaling...